JP5622390B2
(ja)
|
2006-07-18 |
2014-11-12 |
サノフイ |
癌治療用対epha2アンタゴニスト抗体
|
EP1914242A1
(fr)
|
2006-10-19 |
2008-04-23 |
Sanofi-Aventis |
Nouveau anticorps Anti-CD38 pour le traitement du cancer
|
ES2435779T3
(es)
*
|
2007-07-19 |
2013-12-23 |
Sanofi |
Agentes citotóxicos que comprenden nuevos derivados de tomaimicina y su uso terapéutico
|
GB0819097D0
(en)
|
2008-10-17 |
2008-11-26 |
Spirogen Ltd |
Pyrrolobenzodiazepines
|
EP3100745B1
(fr)
|
2009-02-05 |
2018-04-18 |
Immunogen, Inc. |
Nouveaux dérivés de benzodiazépine
|
FR2947269B1
(fr)
|
2009-06-29 |
2013-01-18 |
Sanofi Aventis |
Nouveaux composes anticancereux
|
FR2949469A1
(fr)
*
|
2009-08-25 |
2011-03-04 |
Sanofi Aventis |
Derives anticancereux, leur preparation et leur application en therapeutique
|
AR078470A1
(es)
|
2009-10-02 |
2011-11-09 |
Sanofi Aventis |
Anticuerpos que se unen especificamente al receptor epha2
|
RU2573994C2
(ru)
|
2010-02-10 |
2016-01-27 |
Иммьюноджен, Инк |
Антитела против cd20 и их применение
|
JP5972864B2
(ja)
*
|
2010-04-15 |
2016-08-17 |
メディミューン リミテッド |
ピロロベンゾジアゼピン及びそれらのコンジュゲート
|
JP5870400B2
(ja)
|
2010-04-15 |
2016-03-01 |
シアトル ジェネティクス,インコーポレーテッド |
標的化ピロロベンゾジアゼピンコンジュゲート
|
BR112012026410B8
(pt)
|
2010-04-15 |
2023-01-31 |
Spirogen Dev Sarl |
Composto e conjugado de pirrolobenzodiazepinas e usos dos mesmos
|
FR2963007B1
(fr)
*
|
2010-07-26 |
2013-04-05 |
Sanofi Aventis |
Derives anticancereux, leur preparation et leur application therapeutique
|
KR20140010067A
(ko)
|
2011-02-15 |
2014-01-23 |
이뮤노젠 아이엔씨 |
컨쥬게이트의 제조방법
|
WO2012145112A2
(fr)
*
|
2011-04-18 |
2012-10-26 |
Immunogen, Inc. |
Nouveaux dérivés de maytansinoïdes comprenant un lieur sulfoxyde
|
US20130058947A1
(en)
|
2011-09-02 |
2013-03-07 |
Stem Centrx, Inc |
Novel Modulators and Methods of Use
|
KR101860174B1
(ko)
*
|
2011-09-20 |
2018-05-21 |
메디뮨 리미티드 |
표적 접합체 내의 내포를 위한 비대칭 이량체 pbd 화합물로서 피롤로벤조디아제핀
|
RS54446B1
(en)
*
|
2011-10-14 |
2016-06-30 |
Medimmune Limited |
PIROLOBENZIDIAZEPINE AND ITS CONJUGATES
|
CN103987384A
(zh)
|
2011-10-14 |
2014-08-13 |
西雅图基因公司 |
吡咯并苯并二氮杂卓和靶向结合物
|
EP2751110B1
(fr)
|
2011-10-14 |
2017-04-19 |
MedImmune Limited |
Dérivés asymmetriques de bis-(5H-pyrrolo[2,1-c][1,4]benzodiazépin-5-one) pour le traitement de maladies prolifératives ou auto-immunes
|
WO2013055993A1
(fr)
|
2011-10-14 |
2013-04-18 |
Seattle Genetics, Inc. |
Pyrrolobenzodiazépines et conjugués ciblés
|
WO2013053873A1
(fr)
|
2011-10-14 |
2013-04-18 |
Spirogen Sàrl |
Pyrrolobenzodiazépines
|
SI2817338T1
(sl)
|
2012-02-24 |
2017-11-30 |
Abbvie Stemcentrx Llc |
Modulatorji DLL3 in postopki uporabe
|
KR102099073B1
(ko)
|
2012-02-24 |
2020-04-10 |
애브비 스템센트알엑스 엘엘씨 |
항 sez6 항체들 및 사용 방법
|
AR090549A1
(es)
|
2012-03-30 |
2014-11-19 |
Genentech Inc |
Anticuerpos anti-lgr5 e inmunoconjugados
|
WO2013165940A1
(fr)
|
2012-05-01 |
2013-11-07 |
Genentech, Inc. |
Anticorps anti-pmel17 et immunoconjugués
|
KR102557309B1
(ko)
|
2012-05-15 |
2023-07-20 |
씨젠 인크. |
자가-안정화 링커 접합체
|
WO2013177481A1
(fr)
|
2012-05-25 |
2013-11-28 |
Immunogen, Inc. |
Benzodiazépines et leurs conjugués
|
IN2014DN10652A
(fr)
|
2012-07-09 |
2015-09-11 |
Genentech Inc |
|
AU2013288929A1
(en)
|
2012-07-09 |
2014-12-04 |
Genentech, Inc. |
Immunoconjugates comprising anti-CD22 antibodies
|
RU2015106673A
(ru)
|
2012-08-02 |
2016-09-20 |
Дженентек, Инк. |
Антитела к рецептору эндотелина типа в (etbr) и иммуноконъюгаты
|
EP2887965A1
(fr)
|
2012-08-22 |
2015-07-01 |
ImmunoGen, Inc. |
Dérivés de benzodiazépine cytotoxique
|
US9931414B2
(en)
|
2012-10-12 |
2018-04-03 |
Medimmune Limited |
Pyrrolobenzodiazepine-antibody conjugates
|
EP2906249B1
(fr)
|
2012-10-12 |
2018-06-27 |
MedImmune Limited |
Synthèse et intermédiaires de dérivés de pyrrolobenzodiazépine pour conjugaison
|
US10695433B2
(en)
|
2012-10-12 |
2020-06-30 |
Medimmune Limited |
Pyrrolobenzodiazepine-antibody conjugates
|
CN110256469B
(zh)
|
2012-10-12 |
2022-05-17 |
麦迪穆有限责任公司 |
吡咯并苯并二氮杂卓及其结合物
|
LT2839860T
(lt)
|
2012-10-12 |
2019-07-10 |
Medimmune Limited |
Pirolobenzodiazepinai ir jų konjugatai
|
PL2906253T3
(pl)
|
2012-10-12 |
2019-02-28 |
Adc Therapeutics Sa |
Koniugaty pirolobenzodiazepina-przeciwciało anty-psma
|
RS56520B1
(sr)
|
2012-10-12 |
2018-02-28 |
Adc Therapeutics Sa |
Pirolobenzodiazepin-anti-cd22 konjugati antitela
|
WO2014057114A1
(fr)
|
2012-10-12 |
2014-04-17 |
Adc Therapeutics Sàrl |
Conjugués pyrrolobenzodiazepine-anticorps anti-psma
|
EP2906296B1
(fr)
|
2012-10-12 |
2018-03-21 |
ADC Therapeutics SA |
Conjugués anticorps - pyrrolobenzodiazépine
|
ES2701076T3
(es)
|
2012-11-24 |
2019-02-20 |
Hangzhou Dac Biotech Co Ltd |
Enlazadores hidrofílicos y sus usos para la conjugación de fármacos a las moléculas que se unen a las células
|
EP2745876A1
(fr)
|
2012-12-21 |
2014-06-25 |
Prous Institute for Biomedical Research, S.A. |
Dérivés d'éther d'aminoalkyle de phenyle substitués par substituents hydroxy aliphatique
|
JP6527466B2
(ja)
|
2012-12-21 |
2019-06-05 |
メドイミューン・リミテッドMedImmune Limited |
増殖性疾患および自己免疫疾患の治療に使用するための非対称ピロロベンゾジアゼピンニ量体
|
CN110452242A
(zh)
|
2012-12-21 |
2019-11-15 |
麦迪穆有限责任公司 |
吡咯并苯并二氮杂卓及其结合物
|
DK2958944T3
(da)
|
2013-02-22 |
2019-06-24 |
Abbvie Stemcentrx Llc |
Anti-dll3-antistof-pbd-konjugater og anvendelser deraf
|
CA2905181C
(fr)
|
2013-03-13 |
2020-06-02 |
Medimmune Limited |
Pyrrolobenzodiazepines et ses conjugues servant a fournir une therapie ciblee
|
EA027910B1
(ru)
*
|
2013-03-13 |
2017-09-29 |
Медимьюн Лимитед |
Пирролобензодиазепины и их конъюгаты
|
JP6340019B2
(ja)
|
2013-03-13 |
2018-06-06 |
メドイミューン・リミテッドMedImmune Limited |
ピロロベンゾジアゼピン及びそのコンジュゲート
|
US9562099B2
(en)
|
2013-03-14 |
2017-02-07 |
Genentech, Inc. |
Anti-B7-H4 antibodies and immunoconjugates
|
JP6436965B2
(ja)
|
2013-03-14 |
2018-12-12 |
ジェネンテック, インコーポレイテッド |
抗b7−h4抗体及びイムノコンジュゲート
|
AU2014307080B2
(en)
|
2013-08-12 |
2018-06-07 |
Genentech, Inc. |
1-(chloromethyl)-2,3-dihydro-1H-benzo(E)indole dimer antibody-drug conjugate compounds, and methods of use and treatment
|
MX2016002547A
(es)
|
2013-08-28 |
2016-06-17 |
Stemcentrx Inc |
Metodos de conjugacion de anticuerpos especificos de sitio y composiciones.
|
MX2016002574A
(es)
|
2013-08-28 |
2016-06-14 |
Stemcentrx Inc |
Nuevos moduladores del homologo 6 (sez6) y metodos de uso.
|
EP3041846B1
(fr)
*
|
2013-09-02 |
2018-11-07 |
Hangzhou Dac Biotech Co., Ltd |
Nouveaux agents cytotoxiques pour la conjugaison de médicaments avec la molécule de liaison cellulaire
|
MX2016003248A
(es)
|
2013-09-17 |
2016-06-07 |
Genentech Inc |
Metodos de uso de anticuerpos anti-lgr5.
|
EP3054985B1
(fr)
|
2013-10-11 |
2018-12-26 |
Medimmune Limited |
Conjugués anticorps-pyrrolobenzodiazépine
|
US9956299B2
(en)
|
2013-10-11 |
2018-05-01 |
Medimmune Limited |
Pyrrolobenzodiazepine—antibody conjugates
|
EP3054983B1
(fr)
|
2013-10-11 |
2019-03-20 |
Medimmune Limited |
Conjugués anticorps-pyrrolobenzodiazépines
|
GB201317981D0
(en)
|
2013-10-11 |
2013-11-27 |
Spirogen Sarl |
Pyrrolobenzodiazepines and conjugates thereof
|
GB201317982D0
(en)
|
2013-10-11 |
2013-11-27 |
Spirogen Sarl |
Pyrrolobenzodiazepines and conjugates thereof
|
CA2921707C
(fr)
|
2013-10-15 |
2023-03-28 |
Seattle Genetics, Inc. |
Lieurs de medicaments pegyles pour pharmacocinetique de conjugues ligand-medicament amelioree
|
SG11201603397QA
(en)
|
2013-11-06 |
2016-05-30 |
Stemcentrx Inc |
Novel anti-claudin antibodies and methods of use
|
WO2015089449A2
(fr)
|
2013-12-12 |
2015-06-18 |
Stem Centrx, Inc. |
Nouveaux anticorps anti dpep3 et leurs procédés d'utilisation
|
CA2931340A1
(fr)
|
2013-12-13 |
2015-06-18 |
Genentech, Inc. |
Anticorps et immunoconjugues anti-cd33
|
WO2015095212A1
(fr)
|
2013-12-16 |
2015-06-25 |
Genentech, Inc. |
Composés conjugués anticorps-médicament dimérique à base de 1-(chlorométhyl)-2,3-dihydro-1 h-benzo [e]indole, et méthodes d'utilisation et de traitement
|
WO2015123265A1
(fr)
|
2014-02-11 |
2015-08-20 |
Seattle Genetics, Inc. |
Réduction sélective de protéines
|
PE20161209A1
(es)
|
2014-02-21 |
2016-11-10 |
Abbvie Stemcentrx Llc |
Conjugados de anticuerpos anti-drosophila similar a delta 3 (anti-dll3) y medicamentos para usarse en el tratamiento contra melanoma
|
CN114262344A
(zh)
|
2014-02-28 |
2022-04-01 |
杭州多禧生物科技有限公司 |
带电荷链接体及其在共轭反应上的应用
|
GB201406767D0
(en)
|
2014-04-15 |
2014-05-28 |
Cancer Rec Tech Ltd |
Humanized anti-Tn-MUC1 antibodies anf their conjugates
|
GB201407816D0
(en)
|
2014-05-02 |
2014-06-18 |
King S College London |
Pyrrolobenzodiazepine Compounds
|
RU2016150370A
(ru)
|
2014-05-22 |
2018-06-26 |
Дженентек, Инк. |
Антитела и иммуноконъюгаты против GPC3
|
WO2016008112A1
(fr)
|
2014-07-16 |
2016-01-21 |
Medshine Discovery Inc. |
Lieurs et application à des conjugués anticorps-médicament (acd) associée
|
RU2764074C2
(ru)
|
2014-08-28 |
2022-01-13 |
Байоатла, Ллк |
Условно активные химерные антигенные рецепторы для модифицированных т-клеток
|
SG11201701328XA
(en)
*
|
2014-09-02 |
2017-03-30 |
Immunogen Inc |
Methods for formulating antibody drug conjugate compositions
|
WO2016036804A1
(fr)
|
2014-09-03 |
2016-03-10 |
Immunogen, Inc. |
Dérivés de benzodiazépine cytotoxique
|
JP6606545B2
(ja)
|
2014-09-03 |
2019-11-13 |
イミュノジェン・インコーポレーテッド |
細胞障害性ベンゾジアゼピン誘導体
|
TW201617368A
(zh)
|
2014-09-05 |
2016-05-16 |
史坦森特瑞斯公司 |
新穎抗mfi2抗體及使用方法
|
CN106687141A
(zh)
|
2014-09-10 |
2017-05-17 |
麦迪穆有限责任公司 |
吡咯并苯并二氮杂卓及其缀合物
|
MA40576B1
(fr)
|
2014-09-12 |
2020-11-30 |
Genentech Inc |
Anticorps et immunoconjugués anti-her2
|
AU2015314826A1
(en)
|
2014-09-12 |
2017-03-02 |
Genentech, Inc. |
Cysteine engineered antibodies and conjugates
|
CN113698488A
(zh)
|
2014-09-12 |
2021-11-26 |
基因泰克公司 |
抗-b7-h4抗体及免疫缀合物
|
GB201416112D0
(en)
|
2014-09-12 |
2014-10-29 |
Medimmune Ltd |
Pyrrolobenzodiazepines and conjugates thereof
|
AU2015314744A1
(en)
|
2014-09-12 |
2017-03-02 |
Genentech, Inc. |
Anti-CLL-1 antibodies and immunoconjugates
|
EP3197500A1
(fr)
|
2014-09-17 |
2017-08-02 |
Genentech, Inc. |
Immunoconjugués comprenant des anticorps anti-her2 et des pyrrolobenzodiazépines
|
JP2017533887A
(ja)
|
2014-09-17 |
2017-11-16 |
ジェネンテック, インコーポレイテッド |
ピロロベンゾジアゼピン類及びその抗体ジスルフィドコンジュゲート
|
US10780096B2
(en)
|
2014-11-25 |
2020-09-22 |
Adc Therapeutics Sa |
Pyrrolobenzodiazepine-antibody conjugates
|
PE20171185A1
(es)
|
2015-01-14 |
2017-08-22 |
Bristol Myers Squibb Co |
Dimeros de benzodiazepina unidos con puentes de heteroarileno, conjugados de estos, y sus metodos de preparacion y uso
|
CA2973354A1
(fr)
|
2015-01-14 |
2016-07-21 |
Bristol-Myers Squibb Company |
Dimeres de benzodiazepine, conjugues de ceux-ci, et procedes de fabrication et d'utilisation
|
US9504694B2
(en)
*
|
2015-03-19 |
2016-11-29 |
Cellerant Therapeutics, Inc. |
Isoquinolidinobenzodiazepines
|
GB201506389D0
(en)
|
2015-04-15 |
2015-05-27 |
Berkel Patricius H C Van And Howard Philip W |
Site-specific antibody-drug conjugates
|
GB201506411D0
(en)
|
2015-04-15 |
2015-05-27 |
Bergenbio As |
Humanized anti-axl antibodies
|
GB201506402D0
(en)
|
2015-04-15 |
2015-05-27 |
Berkel Patricius H C Van And Howard Philip W |
Site-specific antibody-drug conjugates
|
WO2016209951A1
(fr)
|
2015-06-23 |
2016-12-29 |
Bristol-Myers Squibb Company |
Formes macrocycliques dimères des benzodiazépines, leurs conjugués, préparation et utilisations
|
NZ739830A
(en)
|
2015-07-12 |
2021-12-24 |
Hangzhou Dac Biotech Co Ltd |
Bridge linkers for conjugation of cell-binding molecules
|
US9839687B2
(en)
|
2015-07-15 |
2017-12-12 |
Suzhou M-Conj Biotech Co., Ltd. |
Acetylenedicarboxyl linkers and their uses in specific conjugation of a cell-binding molecule
|
CN108026103B
(zh)
|
2015-07-21 |
2021-04-16 |
伊缪诺金公司 |
制备细胞毒性苯并二氮杂䓬衍生物的方法
|
MA43345A
(fr)
|
2015-10-02 |
2018-08-08 |
Hoffmann La Roche |
Conjugués anticorps-médicaments de pyrrolobenzodiazépine et méthodes d'utilisation
|
MA43354A
(fr)
|
2015-10-16 |
2018-08-22 |
Genentech Inc |
Conjugués médicamenteux à pont disulfure encombré
|
GB201601431D0
(en)
|
2016-01-26 |
2016-03-09 |
Medimmune Ltd |
Pyrrolobenzodiazepines
|
GB201602356D0
(en)
|
2016-02-10 |
2016-03-23 |
Medimmune Ltd |
Pyrrolobenzodiazepine Conjugates
|
GB201602359D0
(en)
|
2016-02-10 |
2016-03-23 |
Medimmune Ltd |
Pyrrolobenzodiazepine Conjugates
|
CN109843919A
(zh)
|
2016-03-25 |
2019-06-04 |
西雅图基因公司 |
用于制备聚乙二醇化的药物-接头及其中间体的方法
|
EP3443012A4
(fr)
|
2016-04-15 |
2019-09-11 |
Bioatla, LLC |
Anticorps anti-axl, fragments d'anticorps et leurs immunoconjugués et utilisations associées
|
AU2017254674A1
(en)
|
2016-04-21 |
2018-11-01 |
Abbvie Stemcentrx Llc |
Novel anti-BMPR1B antibodies and methods of use
|
GB201607478D0
(en)
|
2016-04-29 |
2016-06-15 |
Medimmune Ltd |
Pyrrolobenzodiazepine Conjugates
|
WO2017196847A1
(fr)
|
2016-05-10 |
2017-11-16 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Anticorps anti-nouveau récepteur variable d'antigène (vnar) et conjugués d'anticorps ciblant des antigènes tumoraux et viraux
|
TW201808336A
(zh)
|
2016-05-11 |
2018-03-16 |
賽諾菲公司 |
用抗muc1類美登素免疫綴合物抗體治療腫瘤的治療方案
|
RS63698B1
(sr)
|
2016-05-13 |
2022-11-30 |
Bioatla Inc |
Anti-ror2 antitela, fragmenti antitela, njihovi imunokonjugati i njihove upotrebe
|
EP3465221B1
(fr)
|
2016-05-27 |
2020-07-22 |
H. Hoffnabb-La Roche Ag |
Procédé bioanalytique pour la caractérisation de conjugués anticorps-médicament spécifiques d'un site
|
WO2017214182A1
(fr)
|
2016-06-07 |
2017-12-14 |
The United States Of America. As Represented By The Secretary, Department Of Health & Human Services |
Anticorps entièrement humain ciblant pdi pour l'immunothérapie anticancéreuse
|
US11066479B2
(en)
|
2016-08-02 |
2021-07-20 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Monoclonal antibodies targeting glypican-2 (GPC2) and use thereof
|
CA3032147A1
(fr)
|
2016-08-09 |
2018-02-15 |
Seattle Genetics, Inc. |
Conjugues de medicaments avec des lieurs auto-stabilisants, aux proprietes physiochimiques ameliorees
|
CN109689111B
(zh)
|
2016-08-11 |
2024-04-05 |
基因泰克公司 |
吡咯并苯并二氮杂䓬前药及其抗体缀合物
|
GB201617466D0
(en)
|
2016-10-14 |
2016-11-30 |
Medimmune Ltd |
Pyrrolobenzodiazepine conjugates
|
KR20220147721A
(ko)
|
2016-11-14 |
2022-11-03 |
항저우 디에이씨 바이오테크 씨오, 엘티디 |
결합 링커, 그러한 결합 링커를 함유하는 세포 결합 분자-약물 결합체, 링커를 갖는 그러한 결합체의 제조 및 사용
|
AU2017361887B2
(en)
|
2016-11-21 |
2019-08-15 |
Cureab Gmbh |
Anti-GP73 antibodies and immunoconjugates
|
JP7244987B2
(ja)
|
2016-12-14 |
2023-03-23 |
シージェン インコーポレイテッド |
多剤抗体薬物コンジュゲート
|
US11236171B2
(en)
|
2016-12-21 |
2022-02-01 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Human monoclonal antibodies specific for FLT3 and uses thereof
|
DK3579883T3
(da)
|
2017-02-08 |
2021-09-06 |
Adc Therapeutics Sa |
Pyrrolobenzodiazepin-antistofkonjugater
|
GB201702031D0
(en)
|
2017-02-08 |
2017-03-22 |
Medlmmune Ltd |
Pyrrolobenzodiazepine-antibody conjugates
|
JP6671555B2
(ja)
|
2017-02-08 |
2020-03-25 |
アーデーセー セラピューティクス ソシエテ アノニム |
ピロロベンゾジアゼピン抗体複合体
|
MX2019010769A
(es)
|
2017-03-24 |
2019-12-11 |
Seattle Genetics Inc |
Proceso para la preparacion de enlazadores de farmacos de glucuronidos y compuestos intermediarios de los mismos.
|
AU2018255876B2
(en)
|
2017-04-18 |
2020-04-30 |
Medimmune Limited |
Pyrrolobenzodiazepine conjugates
|
US20200129637A1
(en)
|
2017-04-20 |
2020-04-30 |
Adc Therapeutics Sa |
Combination therapy with an anti-axl antibody-drug conjugate
|
WO2018195243A1
(fr)
|
2017-04-20 |
2018-10-25 |
Immunogen, Inc. |
Dérivés de benzodiazépine cytotoxiques et leurs conjugués
|
EP3625256A1
(fr)
|
2017-05-19 |
2020-03-25 |
The U.S.A. as represented by the Secretary, Department of Health and Human Services |
Anticorps monoclonal humain ciblant tnfr2 en immunothérapie anticancéreuse
|
AU2018285562B2
(en)
|
2017-06-14 |
2024-01-18 |
Adc Therapeutics Sa |
Dosage regimes for the administration of an anti-CD19 ADC
|
WO2019006280A1
(fr)
|
2017-06-30 |
2019-01-03 |
Lentigen Technology, Inc. |
Anticorps monoclonaux humains spécifiques de cd33 et leurs procédés d'utilisation
|
WO2019005208A1
(fr)
|
2017-06-30 |
2019-01-03 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Anticorps de la mésothéline humaine et utilisations dans une thérapie anticancéreuse
|
AU2018316532B2
(en)
|
2017-08-18 |
2022-11-24 |
Medimmune Limited |
Pyrrolobenzodiazepine conjugates
|
US20200216463A1
(en)
|
2017-09-20 |
2020-07-09 |
Ph Pharma Co., Ltd. |
Thailanstatin analogs
|
CA3125713A1
(en)
|
2017-09-29 |
2019-04-04 |
Daiichi Sankyo Company, Limited |
Antibody-pyrrolobenzodiazepine derivative conjugate
|
BR112020008676A2
(pt)
*
|
2017-11-02 |
2020-10-27 |
Ube Industries, Ltd. |
composto, e, composição farmacêutica.
|
CN111417409B
(zh)
|
2017-11-14 |
2022-07-08 |
麦迪穆有限责任公司 |
吡咯并苯并二氮杂䓬缀合物
|
WO2019133652A1
(fr)
|
2017-12-28 |
2019-07-04 |
Immunogen, Inc. |
Dérivés de benzodiazépine
|
GB201803342D0
(en)
|
2018-03-01 |
2018-04-18 |
Medimmune Ltd |
Methods
|
GB201806022D0
(en)
|
2018-04-12 |
2018-05-30 |
Medimmune Ltd |
Pyrrolobenzodiazepines and conjugates thereof
|
EP3801630A1
(fr)
|
2018-05-25 |
2021-04-14 |
Medimmune Limited |
Conjugués de pyrrolobenzodiazépine
|
JP7459043B2
(ja)
|
2018-07-12 |
2024-04-01 |
ザ ユナイテッド ステイツ オブ アメリカ, アズ リプレゼンテッド バイ ザ セクレタリー, デパートメント オブ ヘルス アンド ヒューマン サービシーズ |
親和性成熟cd22特異的モノクローナル抗体およびその使用
|
US20210308275A1
(en)
|
2018-07-31 |
2021-10-07 |
Astrazeneca Ab |
Linkers and conjugates
|
CN112585163A
(zh)
|
2018-08-08 |
2021-03-30 |
美国政府(由卫生和人类服务部的部长所代表) |
靶向磷脂酰肌醇蛋白聚糖-2的高亲和力单克隆抗体及其用途
|
CN112867510A
(zh)
|
2018-10-19 |
2021-05-28 |
免疫医疗有限公司 |
吡咯并苯并二氮杂䓬缀合物
|
WO2020079229A1
(fr)
|
2018-10-19 |
2020-04-23 |
Medimmune Limited |
Conjugués de pyrrolobenzodiazépine
|
US20220347309A1
(en)
|
2018-12-19 |
2022-11-03 |
Adc Therapeutics Sa |
Pyrrolobenzodiazepine resistance
|
GB201820725D0
(en)
|
2018-12-19 |
2019-01-30 |
Adc Therapeutics Sarl |
Pyrrolobenzodiazepine resistance
|
JP2022513482A
(ja)
|
2018-12-21 |
2022-02-08 |
アビディティー バイオサイエンシーズ,インク. |
抗トランスフェリン受容体抗体およびその使用
|
US20220096641A1
(en)
*
|
2019-01-03 |
2022-03-31 |
Legochem Biosciences, Inc. |
Pyrrolobenzodiazepine dimer compound with improved safety and use thereof
|
EP3883608A1
(fr)
|
2019-01-08 |
2021-09-29 |
The United States of America, as represented by the Secretary, Department of Health and Human Services |
Anticorps à domaine unique hétérospécifiques ciblant la mésothéline pour le traitement de tumeurs solides
|
CN113784987A
(zh)
|
2019-01-22 |
2021-12-10 |
美国政府(由卫生和人类服务部的部长所代表) |
靶向磷脂酰肌醇蛋白聚糖-1的高亲和力单克隆抗体和使用方法
|
CN116063520A
(zh)
|
2019-01-30 |
2023-05-05 |
真和制药有限公司 |
抗gal3抗体及其用途
|
EP3938372B1
(fr)
|
2019-03-15 |
2023-10-25 |
MedImmune Limited |
Dimères d'azétidobenzodiazépine et conjugués les comprenant destinés à être utilisés dans le traitement du cancer
|
WO2020200880A1
(fr)
|
2019-03-29 |
2020-10-08 |
Medimmune Limited |
Composés et conjugués correspondants
|
US20230094471A1
(en)
|
2019-03-29 |
2023-03-30 |
Immunogen, Inc. |
Cytotoxic bis-benzodiazepine derivatives and conjugates thereof with cell-binding agents for inhibiting abnormal cell growth or for treating proliferative diseases
|
GB201908128D0
(en)
|
2019-06-07 |
2019-07-24 |
Adc Therapeutics Sa |
Pyrrolobenzodiazepine-antibody conjugates
|
CN110483504B
(zh)
*
|
2019-08-02 |
2022-04-26 |
桂林理工大学 |
以DMF为甲酰化试剂构建2-(2-萘基)咪唑[1,2-a]吡啶-3-醛的新方法
|
EP4045511A1
(fr)
*
|
2019-10-16 |
2022-08-24 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Détection visuelle de réticulations d'adn induites par pbd
|
AU2020370125A1
(en)
|
2019-10-22 |
2022-05-19 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
High affinity nanobodies targeting B7H3 (CD276) for treating multiple solid tumors
|
WO2021080608A1
(fr)
|
2019-10-25 |
2021-04-29 |
Medimmune, Llc |
Fraction ramifiée destinée à être utilisée dans des conjugués
|
EP4041769A1
(fr)
|
2019-12-12 |
2022-08-17 |
The United States of America, as represented by the Secretary, Department of Health and Human Services |
Conjugués anticorps-médicament spécifiques à cd276 et leurs utilisations
|
TW202140076A
(zh)
|
2020-01-22 |
2021-11-01 |
英商梅迪繆思有限公司 |
化合物及其軛合物
|
KR20220130749A
(ko)
|
2020-01-22 |
2022-09-27 |
메디뮨 리미티드 |
화합물 및 이의 접합체
|
CN115666589A
(zh)
|
2020-03-19 |
2023-01-31 |
艾维迪提生物科学公司 |
治疗面肩肱型肌营养不良的组合物和方法
|
CN115697418A
(zh)
|
2020-03-27 |
2023-02-03 |
艾维迪提生物科学公司 |
治疗肌营养不良的组合物和方法
|
EP4132588A1
(fr)
|
2020-04-10 |
2023-02-15 |
Seagen Inc. |
Lieurs de variants de charge
|
WO2022093745A1
(fr)
|
2020-10-26 |
2022-05-05 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Anticorps à domaine unique ciblant une protéine de spicule de coronavirus responsable du sars et leurs utilisations
|
WO2022198232A1
(fr)
|
2021-03-18 |
2022-09-22 |
Seagen Inc. |
Libération sélective de médicament à partir de conjugués internalisés de composés biologiquement actifs
|
CA3213636A1
(fr)
|
2021-03-18 |
2022-09-22 |
Seagen Inc. |
Liberation selective de medicament a partir de conjugues internalises de composes biologiquement actifs
|
GB202105187D0
(en)
|
2021-04-12 |
2021-05-26 |
Medimmune Ltd |
Pyrrolobenzodiazepine conjugates
|
GB202105186D0
(en)
|
2021-04-12 |
2021-05-26 |
Medimmune Ltd |
Pyrrolobenzodiazepine conjugates
|
WO2022232612A1
(fr)
|
2021-04-29 |
2022-11-03 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Nanocorps spécifiques du virus de lassa et leurs méthodes d'utilisation
|
CA3216228A1
(fr)
|
2021-06-09 |
2022-12-15 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Anticorps a domaine unique heterospecifiques ciblant pd-l1 pour le traitement de tumeurs solides
|
GB202110726D0
(en)
|
2021-07-26 |
2021-09-08 |
Cambridge Entpr Ltd |
Conjugating reagents and conjugates thereof
|
CA3231330A1
(fr)
|
2021-09-16 |
2023-03-23 |
Avidity Biosciences, Inc. |
Compositions et methodes de traitement d'une dystrophie musculaire facio-scapulo-humerale
|
WO2023215737A1
(fr)
|
2022-05-03 |
2023-11-09 |
Genentech, Inc. |
Anticorps anti-ly6e, immunoconjugués et leurs utilisations
|
GB202207691D0
(en)
|
2022-05-25 |
2022-07-06 |
Cambridge Entpr Ltd |
Quinone protected forms and conjugates
|